AbCellera Biologics (ABCL) Long-Term Debt Issuances (2020 - 2024)
AbCellera Biologics' Long-Term Debt Issuances history spans 3 years, with the latest figure at $3.1 million for Q3 2024.
- For the quarter ending Q3 2024, Long-Term Debt Issuances fell 52.71% year-over-year to $3.1 million, compared with a TTM value of $14.2 million through Sep 2024, up 115.84%, and an annual FY2021 reading of $872000.0, down 94.37% over the prior year.
- Long-Term Debt Issuances for Q3 2024 was $3.1 million at AbCellera Biologics, up from $2.4 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $16.2 million in Q1 2020, with the low at -$662000.0 in Q2 2020.
- Average Long-Term Debt Issuances over 3 years is $3.7 million, with a median of $2.2 million recorded in 2024.
- Biggest YoY gain for Long-Term Debt Issuances was 52.71% in 2024; the steepest drop was 52.71% in 2024.
- Tracing ABCL's Long-Term Debt Issuances over 3 years: stood at -$26000.0 in 2020, then surged by 25330.77% to $6.6 million in 2023, then tumbled by 52.71% to $3.1 million in 2024.
- Per Business Quant, the three most recent readings for ABCL's Long-Term Debt Issuances are $3.1 million (Q3 2024), $2.4 million (Q2 2024), and $2.1 million (Q1 2024).